116 related articles for article (PubMed ID: 27789750)
1. Metabolic Signature on 18F-FDG PET/CT, HER2 Status, and Survival in Gastric Adenocarcinomas.
Celli R; Colunga M; Patel N; Djekidel M; Jain D
J Nucl Med Technol; 2016 Dec; 44(4):234-238. PubMed ID: 27789750
[TBL] [Abstract][Full Text] [Related]
2. Relationship Between 18F-FDG PET/CT Findings and HER2 Expression in Gastric Cancer.
Chen R; Zhou X; Liu J; Huang G
J Nucl Med; 2016 Jul; 57(7):1040-4. PubMed ID: 26966162
[TBL] [Abstract][Full Text] [Related]
3. The correlation between molecular pathological profiles and metabolic parameters of
Song J; Li Z; Chen P; Zhou N; Zhang Y; Yang Z; Wang X
Abdom Radiol (NY); 2020 Feb; 45(2):312-321. PubMed ID: 31111196
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of volume-based parameters using
Park JS; Lee N; Beom SH; Kim HS; Lee CK; Rha SY; Chung HC; Yun M; Cho A; Jung M
Gastric Cancer; 2018 Mar; 21(2):213-224. PubMed ID: 28643145
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma.
Lim SM; Kim H; Kang B; Kim HS; Rha SY; Noh SH; Hyung WJ; Cheong JH; Kim HI; Chung HC; Yun M; Cho A; Jung M
Ann Nucl Med; 2016 May; 30(4):279-86. PubMed ID: 26837515
[TBL] [Abstract][Full Text] [Related]
6. The clinical implications of FDG-PET/CT differ according to histology in advanced gastric cancer.
Chon HJ; Kim C; Cho A; Kim YM; Jang SJ; Kim BO; Park CH; Hyung WJ; Ahn JB; Noh SH; Yun M; Rha SY
Gastric Cancer; 2019 Jan; 22(1):113-122. PubMed ID: 29948387
[TBL] [Abstract][Full Text] [Related]
7. [Correlations of
Wang JL; Shi AQ; Fan CC; Wang YZ; Guo GR; Liu JY
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2022 Aug; 44(4):628-635. PubMed ID: 36065696
[TBL] [Abstract][Full Text] [Related]
8. SUVmax of 18F-FDG PET/CT correlates to expression of major chemotherapy-related tumor markers and serum tumor markers in gastric adenocarcinoma patients.
Bai L; Guo CH; Zhao Y; Gao JG; Li M; Shen C; Guo YM; Duan XY
Oncol Rep; 2017 Jun; 37(6):3433-3440. PubMed ID: 28498457
[TBL] [Abstract][Full Text] [Related]
9. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
10. Prospective Evaluation of Changes in Tumor Size and Tumor Metabolism in Patients with Advanced Gastric Cancer Undergoing Chemotherapy: Association and Clinical Implication.
Park S; Ha S; Kwon HW; Kim WH; Kim TY; Oh DY; Cheon GJ; Bang YJ
J Nucl Med; 2017 Jun; 58(6):899-904. PubMed ID: 28572288
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
[TBL] [Abstract][Full Text] [Related]
12. 18F-FDG PET/CT metabolic parameters and HER2 expression in colorectal cancer.
Yang Z; Liu S; Sun Y; Xu J; Jiang J; Ma X; Zhang Y; Song S
Neoplasma; 2021 Jul; 68(4):875-881. PubMed ID: 33998235
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma.
Hyun SH; Choi JY; Shim YM; Kim K; Lee SJ; Cho YS; Lee JY; Lee KH; Kim BT
Ann Surg Oncol; 2010 Jan; 17(1):115-22. PubMed ID: 19826877
[TBL] [Abstract][Full Text] [Related]
14. Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer.
Ohara M; Shigematsu H; Tsutani Y; Emi A; Masumoto N; Ozaki S; Kadoya T; Okada M
Breast; 2013 Oct; 22(5):958-63. PubMed ID: 23756383
[TBL] [Abstract][Full Text] [Related]
15. 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.
Gebhart G; Gámez C; Holmes E; Robles J; Garcia C; Cortés M; de Azambuja E; Fauria K; Van Dooren V; Aktan G; Coccia-Portugal MA; Kim SB; Vuylsteke P; Cure H; Eidtmann H; Baselga J; Piccart M; Flamen P; Di Cosimo S
J Nucl Med; 2013 Nov; 54(11):1862-8. PubMed ID: 24092940
[TBL] [Abstract][Full Text] [Related]
16. Relationship between PD-L1 expression and
Chen R; Chen Y; Huang G; Liu J
Aging (Albany NY); 2019 Dec; 11(24):12270-12277. PubMed ID: 31848322
[TBL] [Abstract][Full Text] [Related]
17. Fluorodeoxyglucose-positron emission tomography in adenocarcinomas of the distal esophagus and cardia.
Ott K; Weber WA; Fink U; Helmberger H; Becker K; Stein HJ; Müller J; Schwaiger M; Siewert JR
World J Surg; 2003 Sep; 27(9):1035-9. PubMed ID: 12917760
[TBL] [Abstract][Full Text] [Related]
18. Associations between the standardized uptake value of (18)F-FDG PET/CT and the prognostic factors of invasive lobular carcinoma: in comparison with invasive ductal carcinoma.
Jung NY; Kim SH; Choi BB; Kim SH; Sung MS
World J Surg Oncol; 2015 Mar; 13():113. PubMed ID: 25889560
[TBL] [Abstract][Full Text] [Related]
19. Hyperaccumulation of (18)F-FDG in order to differentiate solid pseudopapillary tumors from adenocarcinomas and from neuroendocrine pancreatic tumors and review of the literature.
Guan ZW; Xu BX; Wang RM; Sun L; Tian JH
Hell J Nucl Med; 2013; 16(2):97-102. PubMed ID: 23687644
[TBL] [Abstract][Full Text] [Related]
20. HER2 status in Gastric and Gastroesophageal Junction Adenocarcinoma.
Rima FA; Hussain M; Haque N; Dewan RK; Rahman N; Jinnah MA; Jeba R; Chowdhury F
Mymensingh Med J; 2017 Apr; 26(2):372-379. PubMed ID: 28588175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
